Some previous studies showed the association between migraine and inflammation. The evidence also demonstrated the effectiveness of coenzyme Q10 against migraine, but no published study has investigated the anti-inflammatory effects of CoQ10 in patients with migraine. Thus the present study revealed that CoQ10 supplementation might decrease CGRP and TNF-α with no favourable effects on IL-6 and IL-10 in patients with migraine.

Inflammation and migraine are associated. As the Coenzyme Q10 (CoQ10) as an inflammatory agent provides beneficial impacts in many health issues, therefore this study determines the effects of CoQ10 supplementation in concern of inflammation and migraine.

A total of 45 non-menopausal women with episodic migraine were selected for the analysis. The subjects either obtained placebo or 400 mg/day CoQ10 after the one-month run-in period. All participants also obtained prophylactic medication as well. Serum calcitonin gene-related peptide (CGRP), tumour necrosis factor-α (TNF-α), interleukin (IL)-6, IL-10 and CoQ10 concentration, were assessed at baseline and after the treatment.

A reduction was seen in the  TNF-α, and  CGRP was seen using the CoQ10 supplementation; however, groups exhibited no differences in serum IL-10 and IL-6. Considerable improvement in serum CoQ10 levels was observed with CoQ10 therapy. Also, a significant increase was noticed in the duration, frequency, and severity of the migraine attacks by the patients of the CoQ10 group than placebo.

The CoQ10 supplementation saw a decrease in TNF-α and CGRP with no favourable impacts on IL-6 and IL-10 among the migraine patients.